These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33485895)

  • 1. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
    Chick RC; Clifton GT; Hale DF; Vreeland TJ; Hickerson AT; Kemp Bohan PM; McCarthy PM; Litton JK; Alatrash G; Murthy RK; Qiao N; Philips A; Lukas J; Holmes JP; Mittendorf EA; Peoples GE
    Clin Immunol; 2021 Apr; 225():108679. PubMed ID: 33485895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.
    Clifton GT; Hale D; Vreeland TJ; Hickerson AT; Litton JK; Alatrash G; Murthy RK; Qiao N; Philips AV; Lukas JJ; Holmes JP; Peoples GE; Mittendorf EA
    Clin Cancer Res; 2020 Jun; 26(11):2515-2523. PubMed ID: 32071118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
    Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Litton JK; Shumway NM; Hale DF; Murray JL; Perez SA; Ponniah S; Baxevanis CN; Papamichail M; Peoples GE
    Oncotarget; 2016 Oct; 7(40):66192-66201. PubMed ID: 27589688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
    Mittendorf EA; Clifton GT; Holmes JP; Schneble E; van Echo D; Ponniah S; Peoples GE
    Ann Oncol; 2014 Sep; 25(9):1735-1742. PubMed ID: 24907636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
    Clifton GT; Peace KM; Holmes JP; Vreeland TJ; Hale DF; Herbert GS; Litton JK; Murthy RK; Lukas J; Peoples GE; Mittendorf Elizabeth A
    Clin Immunol; 2019 Apr; 201():48-54. PubMed ID: 30817999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Mittendorf EA; Clifton GT; Holmes JP; Clive KS; Patil R; Benavides LC; Gates JD; Sears AK; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2012 May; 118(10):2594-602. PubMed ID: 21989902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.
    Clifton GT; Litton JK; Arrington K; Ponniah S; Ibrahim NK; Gall V; Alatrash G; Peoples GE; Mittendorf EA
    Ann Surg Oncol; 2017 Aug; 24(8):2161-2167. PubMed ID: 28315060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
    Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
    Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
    Jackson DO; Trappey FA; Clifton GT; Vreeland TJ; Peace KM; Hale DF; Litton JK; Murray JL; Perez SA; Papamichail M; Mittendorf EA; Peoples GE
    Clin Immunol; 2018 Oct; 195():28-35. PubMed ID: 30025819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
    Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
    J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment.
    Zhou Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6711-6718. PubMed ID: 36692548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development and use of the E75 (HER2 369-377) peptide vaccine.
    Clifton GT; Peoples GE; Mittendorf EA
    Future Oncol; 2016 Jun; 12(11):1321-9. PubMed ID: 27044454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
    Mittendorf EA; Lu B; Melisko M; Price Hiller J; Bondarenko I; Brunt AM; Sergii G; Petrakova K; Peoples GE
    Clin Cancer Res; 2019 Jul; 25(14):4248-4254. PubMed ID: 31036542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.